A comparison of antifibrinolytic agents used in hemostatic fibrin sealants

Journal of the American College of Surgeons

Volumn 197, Issue 6, 2003, Pages 1021-1028

  Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR 8; CROSSEAL; FIBRIN GLUE; FIBRINOGEN; QUIXIL; THROMBIN; TRANEXAMIC ACID; HEMOSTATIC AGENT;

ANAPHYLACTIC SHOCK; ANAPHYLAXIS; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FIBRINOLYSIS; FOOD AND DRUG ADMINISTRATION; HEMOSTASIS; HUMAN; NAUSEA; PRIORITY JOURNAL; REVIEW; SKIN ALLERGY; SURGICAL TECHNIQUE; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIRUS TRANSMISSION; BLEEDING; POSTOPERATIVE HEMORRHAGE;

ANTIFIBRINOLYTIC AGENTS; BLOOD LOSS, SURGICAL; FIBRIN TISSUE ADHESIVE; HEMOSTATICS; HUMANS; POSTOPERATIVE HEMORRHAGE;

EID: 0642364474     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2003.07.002     Document Type: Review

References (75)

1. Bergel S. Uber Wirkungen des Fibrins. Dtsch Med Wochenschr. 35:1909;633.
2. Jackson M.R., MacPhee M.J., Drohan W.N., Alving B.M. Fibrin sealant current and potential clinical applications . Blood Coagul Fibrinol. 7:1996;737-746.
3. Cronkite E.P., Lozner E.L., Deaver J. Use of thrombin and fibrinogen in skin grafting. JAMA. 124:1944;976-978.
4. Alving B.M., Weinstein M.J., Finlayson J.S., et al. Fibrin sealant summary of a conference on characteristics and clinical uses . Transfusion. 35:1995;783-790.
5. Martinowitz U., Saltz R. Fibrin sealant. Curr Opin Hematol. 3:1996;395-402.
6. Spotnitz W.D. Fibrin sealant in the United States clinical use at the University of Virginia . Thromb Haemost. 74:1995;482-485.
7. Stricker R.B., Lane P.K., Leffert J.D., et al. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood. 72:1988;1375-1380.
8. Zehnder J.L., Leung L.L. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 76:1990;2011-2016.
9. Banninger H., Hardegger T., Tobler A., et al. Fibrin glue in surgery frequent development of inhibitors of bovine thrombin and human factor V . Br J Haematol. 85:1993;528-532.
10. Flaherty M.J., Henderson R., Wener M.H. Iatrogenic immunization with bovine thrombin a mechanism for prolonged thrombin times after surgery . Ann Intern Med. 111:1989;631-634.
11. Baxter Healthcare Corp. Tisseel VH package insert. Glendale, CA: Baxter Healthcare; 2000.
12. American Red Cross. Crosseal fibrin sealant (human) package insert. Washington, DC: American Red Cross; 2003.
13. Mann K.G., Gaffney D., Bovill E.G. Molecular biology, biochemstry, and lifespan of plasma coagulation factors. Beutler E., Lichtman M.A., Coller B.S., et al. Williams hematology. 5th ed:1995;1206-1226 McGraw-Hill, New York.
14. Basu S., Marini C.P., Bauman F.G., et al. Comparative study of biological glues cryoprecipitate glue, two-component fibrin sealant, and "French" glue . Ann Thorac Surg. 60:1995;1255-1262.
15. Baxter Healthcare Corp. Tisseel VH fibrin sealant (monograph). Accessed Dec 3, 2002 (www.tissuesealing.com/us/products/biological/monograph.cfm), vol 2002: Baxter Healthcare; 2002.
16. Levy J.H. Hemostatic agents and their safety. J Cardiothorac Vasc Anesth. 13:(Suppl):1999;6-11.
17. Hardy J.F., Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth. 39:1992;353-365.
18. Hardy J.F., Belisle S. Natural and synthetic antifibrinolytics in adult cardiac surgery efficacy, effectiveness and efficiency . Can J Anaesth. 41:1994;1104-1112.
19. Hunt B.J. Modifying perioperative blood loss. Blood Rev. 5:1991;168-176.
20. Peters D.C., Noble S. Aprotinin an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery . Drugs. 57:1999;233-260.
21. Dunn C.J., Goa K.L. Tranexamic acid a review of its use in surgery and other indications . Drugs. 57:1999;1005-1032.
22. Erstad B.L. Systemic hemostatic medications for reducing surgical blood loss. Ann Pharmacother. 35:2001;925-934.
23. Pipan C.M., Glasheen W.P., Matthew T.L., et al. Effects of antifibrinolytic agents on the life span of fibrin sealant. J Surg Res. 53:1992;402-407.
24. Rakocz M., Mazar A., Varon D., et al. Dental extractions in patients with bleeding disorders. The use of fibrin glue. Oral Surg Oral Med Oral Pathol. 75:1993;280-282.
25. Baudo F., deCataldo F., Landonio G., Muti G. Management of oral bleeding in haemophilic patients. Lancet. 2:1988;1082.
26. Kjaergard H.K., Fairbrother J.E. Controlled clinical studies of fibrin sealant in cardiothoracic surgery a review . Eur J Cardiothorac Surg. 10:1996;727-733.
27. Rousou J., Levitsky S., Gonzalez-Lavin L., et al. Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. A multicenter study. J Thorac Cardiovasc Surg. 97:1989;194-203.
28. Shoemaker WC, Kram HB, Fleming AW. Use of fibrin sealant to decrease mortality and morbidity from traumatic injuries to spleen and liver. Data on file (report 021). Vienna, Austria: Immuno AG, 1991.
29. Shoemaker WC, Kram HB, Fleming AW. Randomized clinical trial of fibrin sealant in closure of temporary colostomies placed for trauma effects on morbidity and mortality. Data on file (report 021). Vienna, Austria: Immuno AG, 1991:679-690.
30. Omrix Biopharmaceuticals. Quixil product monograph. Rhode-St-Genese, Belgium: Omrix Biopharmaceuticals; 2000.
31. Liu M., Lui W.Y. The use of fibrin adhesive for hemostasis after liver resection. Zhonghua Yi Xue Za Zhi (Taipei). 51:1993;19-22.
32. Kohno H., Nagasue N., Chang Y.C., et al. Comparison of topical hemostatic agents in elective hepatic resection a clinical prospective randomized trial . World J Surg. 16:1992;966-969.
33. Noun R., Elias D., Balladur P., et al. Fibrin glue effectiveness and tolerance after elective liver resection a randomized trial . Hepatogastroenterology. 43:1996;221-224.
34. Jackson M.R. Fibrin sealants in surgical practice an overview . Am J Surg. 182:(Suppl 2):2001;1S-7S.
35. Kinahan T.J., Johnson H.W. Tisseel in hypospadias repair. Can J Surg. 35:1992;75-77.
36. Haase J. Use of Tisseel in neurosurgery. J Neurosurg. 61:1984;801.
37. Miyake K., Gotoh M., Sai S. Clinical application of a new fibrin adhesive (Tisseel) in urologic surgery. Hinyokika Kiyo. 31:1985;357-364.
38. Ohsumi N. Postoperative compressive penile dressing using fibrin seal (Tisseel) and tulle gauze for hypospadias repair. Plast Reconstr Surg. 101:1998;1737-1738.
39. Olofsson J., Bynke O. Transantral repair of cerebrospinal fluid fistulas using bone chips, Tisseel, fascia and plaster of Paris. Acta Otolaryngol. 449:(Suppl):1988;89-92.
40. Onotera R.T., Unruh H.W. Closure of a post-pneumonectomy bronchopleural fistula with fibrin sealant (Tisseel). Thorax. 43:1988;1015-1016.
41. Raborn G.W., Hohn F.I., Grace M.G., Arora B.K. Tisseel, a two component fibrin tissue sealant system report of a trial involving anticoagulated dental patients . J Can Dent Assoc. 56:1990;779-781.
42. Thorup J., Schultz A., Christiansen L. Treatment of testicular hydroceles with puncture and injection of fibrin glue (Tisseel). Ugeskr Laeger. 148:1986;1759-1760.
43. Vibe P., Pless J. Tisseel. A new method of attaching skin grafts. Ugeskr Laeger. 145:1983;563-564.
44. Wiseman N.E. Endoscopic closure of recurrent tracheoesophageal fistula using Tisseel. J Pediatr Surg. 30:1995;1236-1237.
45. Vaiman M., Eviatar E., Segal S. The use of fibrin glue as hemostatic in endonasal operations a prospective, randomized study . Rhinology. 40:2002;185-188.
46. Vaiman M., Segal S., Eviatar E. Fibrin glue treatment for epistaxis. Rhinology. 40:2002;88-91.
47. Vaiman M., Eviatar E., Segal S. Effectiveness of second-generation fibrin glue in endonasal operations. Otolaryngol Head Neck Surg. 126:2002;388-391.
48. Fremes S.E., Wong B.I., Lee E., et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg. 58:1994;1580-1588.
49. Laupacis A., Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery meta-analysis using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators . Anesth Analg. 85:1997;1258-1267.
50. Casati V., Guzzon D., Oppizzi M., et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations effects on perioperative bleeding and allogeneic transfusions . J Thorac Cardiovasc Surg. 120:2000;520-527.
51. Wong B.I., McLean R.F., Fremes S.E., et al. Aprotinin and tranexamic acid for high transfusion risk cardiac surgery. Ann Thorac Surg. 69:2000;808-816.
52. Cicek S., Tatar H., Demirkilic U., Kuralay E. Topical use of aprotinin in cardiac surgery. J Thorac Cardiovasc Surg. 110:1995;568-569.
53. Edmunds L.H. Jr. Invited letter concerning topical aprotinin . J Thorac Cardiovasc Surg. 109:1995;400-402.
54. Tabuchi N., de Hoan J., van Oeveren W. Topical effect of aprotinin on the surgical wound in cardiac surgery. J Thorac Cardiovasc Surg. 109:1995;399-400.
55. O'Regan D.J., Giannopoulos N., Mediratta N., et al. Topical aprotinin in cardiac operations. Ann Thorac Surg. 58:1994;778-781.
56. Isgro F., Stanisch O., Kiessling A.H., et al. Topical application of aprotinin in cardiac surgery. Perfusion. 17:2002;347-351.
57. Mand'ak J., Lonsky V., Dominik J. Topical use of aprotinin in coronary artery bypass surgery. Acta Medica. 42:1999;139-144.
58. Coker N., Higgins D.J. Tranexamic acid applied topically to achieve haemostasis. Anaesthesia. 55:2000;600-601.
59. De Bonis M., Cavaliere F., Alessandrini F., et al. Topical use of tranexamic acid in coronary artery bypass operations a double-blind, prospective, randomized, placebo-controlled study . J Thorac Cardiovasc Surg. 119:2000;575-580.
60. Waly N.G. Local antifibrinolytic treatment with tranexamic acid in hemophilic children undergoing dental extractions. Egypt Dent J. 41:1995;961-968.
61. Scheule A.M., Jurmann M.J., Wendel H.P., et al. Anaphylactic shock after aprotinin reexposure time course of aprotinin-specific antibodies . Ann Thorac Surg. 63:1997;242-244.
62. Beierlein W, Scheule AM, Ziemer G. Anaphylactic aprotinin reaction. Ann Thorac Surg 2000;69:1298.
63. Ryckwaert Y., Barthelet Y., Bonnet-Boyer M.C., et al. Anaphylactic shock after a test-dose of aprotinin in pediatric orthopedic surgery. Ann Fr Anesth Reanim. 18:1999;904-908.
64. Dietrich W., Spath P., Ebell A., Richter J.A. Prevalence of anaphylactic reactions to aprotinin analysis of two hundred forty-eight reexposures to aprotinin in heart operations . J Thorac Cardiovasc Surg. 113:1997;194-201.
65. Beierlein W., Scheule A.M., Antoniadis G., et al. An immediate, allergic skin reaction to aprotinin after reexposure to fibrin sealant. Transfusion. 40:2000;302-305.
66. Scheule A.M., Beierlein W., Wendel H.P., et al. Fibrin sealant, aprotinin, and immune response in children undergoing operations for congenital heart disease. J Thorac Cardiovasc Surg. 115:1998;883-889.
67. Scheule A.M., Beierlein W., Lorenz H., Ziemer G. Repeated anaphylactic reactions to aprotinin in fibrin sealant. Gastrointest Endosc. 48:1998;83-85.
68. Scheule A.M., Beierlein W., Wendel H.P., et al. Aprotinin in fibrin tissue adhesives induces specific antibody response and increases antibody response of high-dose intravenous application. J Thorac Cardiovasc Surg. 118:1999;348-353.
69. Orsel I., Guillaume A., Feiss P. Anaphylactic shock caused by fibrin glue. Ann Fr Anesth Reanim. 16:1997;292-293.
70. Kon N.F., Masumo H., Nakajima S., et al. Anaphylactic reaction to aprotinin following topical use of biological tissue sealant. Masui. 43:1994;1606-1610.
71. Horowitz B., Prince A.M., Horowitz M.S., Watklevicz C. Viral safety of solvent-detergent treated blood products. Dev Biol Stand. 81:1993;147-161.
72. Wilson S.M., Pell P., Donegan E.A. HIV 1 transmission following the use of cryoprecipitated fibrinogen as gel/adhesive. [abstract] Transfusion. 31:1991;51.
73. Vankemmel O., de La Taille A., Burnouf T., et al. Evaluation of a fibrin sealant free of bovine-derived components in an experimental vas anastomosis study. Urol Int. 65:2000;196-199.
74. Ortel T.L., Charles L.A., Keller F.G., et al. Topical thrombin and acquired coagulation factor inhibitors clinical spectrum and laboratory diagnosis . Am J Hematol. 45:1994;128-135.
75. Rapaport S.I., Zivelin A., Minow R.A., et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol. 97:1992;84-91.